Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
Posts Positive Organic Growth and Adjusted EBITDA‎1 of 23.5% of Revenue CINCINNATI,…
ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug…
Drger Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation
Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in…
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…